These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25158954)

  • 1. The role of hypoxia and exploitation of the hypoxic environment in hematologic malignancies.
    Muz B; de la Puente P; Azab F; Luderer M; Azab AK
    Mol Cancer Res; 2014 Oct; 12(10):1347-54. PubMed ID: 25158954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer associated fibroblasts in hematological malignancies.
    Raffaghello L; Vacca A; Pistoia V; Ribatti D
    Oncotarget; 2015 Feb; 6(5):2589-603. PubMed ID: 25474039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy.
    Baran N; Konopleva M
    Clin Cancer Res; 2017 May; 23(10):2382-2390. PubMed ID: 28137923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting hypoxia in solid and haematological malignancies.
    Harris B; Saleem S; Cook N; Searle E
    J Exp Clin Cancer Res; 2022 Nov; 41(1):318. PubMed ID: 36320041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exosomes promote bone marrow angiogenesis in hematologic neoplasia: the role of hypoxia.
    Ohyashiki JH; Umezu T; Ohyashiki K
    Curr Opin Hematol; 2016 May; 23(3):268-73. PubMed ID: 26866730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hypoxia signalling pathway in haematological malignancies.
    Irigoyen M; García-Ruiz JC; Berra E
    Oncotarget; 2017 May; 8(22):36832-36844. PubMed ID: 28415662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor hypoxia and targeted gene therapy.
    Greco O; Scott S
    Int Rev Cytol; 2007; 257():181-212. PubMed ID: 17280898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eicosanoids and other lipid mediators and the tumor hypoxic microenvironment.
    Krishnamoorthy S; Honn KV
    Cancer Metastasis Rev; 2011 Dec; 30(3-4):613-8. PubMed ID: 22042480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of stem cell landscape and assessing the stemness degree to aid clinical therapeutics in hematologic malignancies.
    Feng YD; Du J; Chen HL; Shen Y; Jia YC; Zhang PY; He A; Yang Y
    Sci Rep; 2024 Oct; 14(1):23743. PubMed ID: 39390242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Can tumor hypoxia be turned into a chemotherapeutic advantage?].
    Trédan O; Grantab R; Dumontet C
    Bull Cancer; 2008 May; 95(5):528-34. PubMed ID: 18541517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell physiology regulation by hypoxia inducible factor-1: Targeting oxygen-related nanomachineries of hypoxic cells.
    Eskandani M; Vandghanooni S; Barar J; Nazemiyeh H; Omidi Y
    Int J Biol Macromol; 2017 Jun; 99():46-62. PubMed ID: 28223135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of cell death in the tumor microenvironment.
    Wouters BG; Koritzinsky M; Chiu RK; Theys J; Buijsen J; Lambin P
    Semin Radiat Oncol; 2003 Jan; 13(1):31-41. PubMed ID: 12520462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the vascular endothelial growth factor in hematologic malignancies.
    Paesler J; Gehrke I; Poll-Wolbeck SJ; Kreuzer KA
    Eur J Haematol; 2012 Nov; 89(5):373-84. PubMed ID: 22928557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NADPH oxidase subunit 4 mediates cycling hypoxia-promoted radiation resistance in glioblastoma multiforme.
    Hsieh CH; Wu CP; Lee HT; Liang JA; Yu CY; Lin YJ
    Free Radic Biol Med; 2012 Aug; 53(4):649-58. PubMed ID: 22713363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxic tumor microenvironment: Implications for cancer therapy.
    Roy S; Kumaravel S; Sharma A; Duran CL; Bayless KJ; Chakraborty S
    Exp Biol Med (Maywood); 2020 Jul; 245(13):1073-1086. PubMed ID: 32594767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From stem cells to cancer stem cells: HIF takes the stage.
    Lee KE; Simon MC
    Curr Opin Cell Biol; 2012 Apr; 24(2):232-5. PubMed ID: 22296771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia inhibits JAK2V617F activation via suppression of SHP-2 function in myeloproliferative neoplasm cells.
    Mitsumori T; Nozaki Y; Kawashima I; Yamamoto T; Shobu Y; Nakajima K; Morishita S; Komatsu N; Kirito K
    Exp Hematol; 2014 Sep; 42(9):783-92.e1. PubMed ID: 24860972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiological response to hypoxia - from the molecular mechanisms of malady to drug discovery: drug discovery for targeting the tumor microenvironment.
    Nagasawa H
    J Pharmacol Sci; 2011; 115(4):446-52. PubMed ID: 21422725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy.
    Meijer TW; Kaanders JH; Span PN; Bussink J
    Clin Cancer Res; 2012 Oct; 18(20):5585-94. PubMed ID: 23071360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of tumor-associated macrophages in hematological malignancies.
    Komohara Y; Niino D; Ohnishi K; Ohshima K; Takeya M
    Pathol Int; 2015 Apr; 65(4):170-6. PubMed ID: 25707506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.